(Q36710270)

15 August 2017

1 reference

title

The current status of intermittent androgen deprivation (IAD) therapy for prostate cancer: putting IAD under the spotlight (English)

1 reference

15 August 2017

1 reference

Ulf Tunn

1

1 reference

15 August 2017

publication date

1 January 2007

1 reference

15 August 2017

1 reference

15 August 2017

volume

99 Suppl 1

1 reference

15 August 2017

page(s)

19-22; discussion 23-4

1 reference

Luteinizing hormone-releasing hormone agonists in prostate cancer. Elimination of flare reaction by pretreatment with cyproterone acetate and low-dose diethylstilbestrol

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2007.06596.X

Enhancement of intermittent androgen ablation by "off-cycle" maintenance with finasteride in LNCaP prostate cancer xenograft model

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2007.06596.X

Intermittent androgen deprivation for locally advanced prostate cancer. Preliminary experience from an ongoing randomized controlled study of the South European urooncological group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2007.06596.X

Fetoscopic placement of a transurethral stent for intrauterine obstructive uropathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2007.06596.X

Long-term side-effects of intermittent androgen suppression therapy in prostate cancer: results of a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2007.06596.X

10.1111/J.1464-410X.2007.06596.X

21 January 2018

Identifiers

DOI

1 reference

15 August 2017

1 reference